Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 9/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 3/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.34 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.33 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2865015 | 0.86 | BTK (0.41) | BTKFGFR1RIOK2 | |
| SCHEMBL2870343 | 0.86 | BTK (0.43) | BTKMAOAPARP1FGFR1FGFR2 | |
| SCHEMBL2872569 | 0.86 | BTK (0.40) | BTKALDH1A1 | |
| SCHEMBL2869208 | 0.84 | BTK (0.39) | BTKALDH1A1RIOK2 | |
| SCHEMBL2861463 | 0.83 | PDE2A (0.35) | BTKMAOADYRK1APDE2ANTRK1 | |
| SCHEMBL2871110 | 0.82 | MAOA (0.40) | MAOADYRK1APDE2APARP1FGFR1 | |
| SCHEMBL2860215 | 0.81 | PDE2A (0.41) | MAOADYRK1APDE2APARP1FGFR1 | |
| SCHEMBL2868101 | 0.80 | MAOA (0.35) | MAOADYRK1APDE2APARP1FGFR1 | |
| SCHEMBL2871146 | 0.79 | MAOA (0.36) | BTKMAOAPDE2APARP1NTRK1 | |
| SCHEMBL5790922 | 0.77 | GAA (0.37) | BTKPDE2AFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842701-B2 | Pyrazoloquinolone derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-30 | — | — | US | disclosed |
| US-7842701-B2 | Pyrazoloquinolone derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-30 | — | — | US | disclosed |
| US-7842701-B2 | Pyrazoloquinolone derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-30 | — | — | US | disclosed |
| US-20070281963-A1 | Pyrazoloquinolone Derivative And Use Thereof | TAKEDA PHARMACEUTICAL COMPANY (JP) | 2007-12-06 | — | — | US | disclosed |
| US-20070281963-A1 | Pyrazoloquinolone Derivative And Use Thereof | TAKEDA PHARMACEUTICAL COMPANY (JP) | 2007-12-06 | — | — | US | disclosed |
| US-20070281963-A1 | Pyrazoloquinolone Derivative And Use Thereof | TAKEDA PHARMACEUTICAL COMPANY (JP) | 2007-12-06 | — | — | US | disclosed |
| EP-1719771-A1 | PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281963-A1 | Pyrazoloquinolone Derivative And Use Thereof | MAP3K20, MAP4K5, MAP4K3 | BTK 272/4885MAOA 2993/4885DYRK1A 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.